NSIH, ALKN, MCCI, DNAG, CLNH, SNSS OTCPicks.com Stocks to Watch for Thursday, January 7th

Our Stocks to Watch tomorrow include NetSpace International Holdings Inc. (OTC: NSIH), Alkane Inc. (OTC: ALKN), Marketing Concepts International Inc. (OTC: MCCI), DNAPrint Genomics Inc. (OTCBB: DNAG), Centerline Holding Co. (OTC: CLNH) and Sunesis Pharmaceuticals Inc. (Nasdaq: SNSS).

NETSPACE INTERNATIONAL HOLDINGS INCORPORATED (OTC: NSIH)

"Up 6,899.99% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/NSIH.php

Netspace International Holdings, Inc. provides web design and custom internet marketing services. It offers clients various critical services designed to transform their website into an integrated marketing tool. The company delivers professionally crafted websites, customized online marketing solutions, e-commerce platforms, and the technology backbone to support superior web performance and reliability to Small and Medium-Sized Enterprises (SME). The company offers critical services, enabling any company to access and leverage the power of the Internet. History Netspace International Holdings, Inc. was founded in 1996.

NSIH News:

January 5 - NetSpace Announces Acquisition of Alternative Fuels Americas

NetSpace International Holdings, Inc. (OTC: NSIH) announced it has fully completed the acquisition of Alternative Fuels Americas (AFA). This Company is a wholly owned subsidiary of NSIH.

Alternative Fuels Americas (AFA) is a biodiesel consolidation company seeking to acquire companies at every phase of the biodiesel cycle, instituting operational efficiencies and reducing the cost of the biodiesel. The Company has a well defined, vertically integrated business model with a number of distinctive and innovative components which it believes can be rapidly and efficiently implemented, including (a) control of feedstock sources via feedstock purchase agreements, (b) operation of in-field extraction and refining facilities, and (c) integrated logistics. The AFA model represents the culmination of 3 years of research and industry involvement, drawing on the lessons learned from evaluating strategies and tactics deployed by the industry pioneers.

New technologies and advances in agricultural practices, as well as new feedstock development, have transformed the economics of biodiesel, allowing for profitable production, particularly under a vertically integrated operational model. Driving the growing market for biodiesel is:

* A desire to reduce dependency on foreign oil.

* A desire to incite economic development, particularly in rural regions.

* A desire to promote clean energy and reduce carbon emissions.

AFA was founded by The Tudog Group, a Florida-based company with business advisory, business development, market research, training, and merchant banking divisions. Tudog was founded in 1999 and has worked with more than 200 companies from 19 countries.

With this transaction Craig Frank was named CEO of the company. "We are very excited about this milestone," stated Mr. Frank, "and AFA being public will allow us to take advantage of the assets of the company. Within the next several months it is our goal to bring all accounting up to date, change the name of company and recapitalize the existing structure."

This transaction was put together by River Rock Capital and Tudog.

ABOUT THE TUDOG GROUP

A Florida based company with business advisory, business development, market research, training and merchant banking divisions. Founded in 1999 and has worked with more than 200 companies like Amdocs Ltd. and Military Resale Group from 19 countries, including throughout Central America. Tudog has been active in Central America since 2005, working with a number of governments, NGOs, and private companies in Costa Rica, Guatemala, Honduras, Nicaragua and El Salvador.

ABOUT RIVER ROCK CAPITAL, LLC

River Rock Capital was founded in Maitland, Florida by experienced seasoned financial professionals. The Company's core competence is company renewal and the structuring of liquidity events. River Rock Capital has worked with more than 30 companies from 11 different industries. The Company's activities have served to raise more than $100 million in capital and established over $700 million in company value.

ABOUT ALTERNATIVE FUELS AMERICAS

Alternative Fuels Americas (AFA) is a biodiesel consolidation company seeking to acquire companies at every phase of the biodiesel cycle, instituting operational efficiencies and reducing the cost of the biodiesel.

ALKANE INCORPORATED (OTC: ALKN)

"Up 154.60% on Wednesday"

Company Profile: http://www.otcpicks.com/alkane-inc.htm  

Alkane, Inc. is dedicated to the development and sales of alternative fuels and additives which reduce the cost of operating and maintaining vehicles. Additional benefits of Alkane, Inc.'s product offerings include positive environmental impact through the reduction of harmful emissions and a lessened U.S. dependence on foreign oil due to a decrease in crude oil dependent diesel fuel consumption.

ALKN News:

October 21 - Dr. Mathew Zuckerman of Alkane, Inc. Receives The Daily Record's 2009 Maryland Innovator of the Year Award

Mathew Zuckerman, Ph.D. of Alkane, Inc. (OTC: ALKN) ("Alkane") has been selected as a winner of The Daily Record's 2009 Innovator of the Year Awards.

The Daily Record began the Innovator of the Year Awards in 2002 as a way to recognize Marylanders and Maryland-based companies for their innovative spirit - for creating new products, new programs, new services, or new processes that have helped their companies, industries, or communities.

"I am honored to have been recognized for my work on Alkane's flagship product, Monster Diesel™," said Zuckerman, who is President & CEO of Alkane, as well as Inventor of patent pending technology on which the Monster Diesel™ product is based. "We have a product that increases diesel fuel's power and MPG, lowers emissions, winterizes fuel, and reduces engine wear. It's just a matter of getting the word out to potential users. This recognition by The Daily Record helps us to do just that."

"The Daily Record's Innovators of the Year have imagination and vision, the ability to see a need and fill it, and the courage to make change happen," says Christopher Eddings, Publisher of The Daily Record. "We applaud Dr. Zuckerman for embodying the innovative spirit."

This year, The Daily Record received more than 80 nominations, which are solicited from The Daily Record's readers, economic development agencies, chambers of commerce, and the business community at large. Nominees are then asked to complete an application which explains their innovation and the impact it has made on Maryland.

A distinguished panel of judges reviewed the applications and selected 25 winners for 2009, including the top Innovator of the Year. The winners were honored on October 14 at a cocktail reception, held at Baltimore's American Visionary Art Museum. Winners also were profiled in a special magazine that was included in the October 16 issue of The Daily Record.

ABOUT THE DAILY RECORD

For 121 years, The Daily Record Company has provided trusted legal and business information to Maryland readers. In addition to the daily newspaper published five days a week, The Daily Record publishes its website, www.mddailyrecord.com, two blogs, On the Record and Eye on Annapolis, and a variety of special publications on topics of interest to Maryland business and legal professionals.

The Daily Record also honors leading Marylanders through events such as Influential Marylanders, Maryland's Top 100 Women, Leadership in Law and Health Care Heroes. The Daily Record is owned by Dolan Media Company, trading as DM, of Minneapolis, MN.

MARKETING CONCEPTS INTERNATIONAL (OTC: MCCI)

"Up 50.00% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/MCCI.php

Marketing Concepts International is positioned to work with smaller companies that we determine are likely to significantly benefit from the acquisition of working capital and professional business guidance. These client corporations will be at the earliest stage of their growth potential, and as such will provide the greatest opportunity for a substantial financial return for our services. The company’s corporate strategy is to provide business development services to smaller corporations and start-ups in exchange for a share of the client corporation's sales revenue. The services provided include: marketing consulting, management consulting, capital acquisition services, web site development, sales consulting, negotiating services, and partnership development.

MCCI News:

May 14 - Seakinetics Corporation Completes Its Intention to Acquire Controlling Interest in Marketing Concepts International Inc.

Marketing Concepts International Inc. (OTC: MCCI) (the "Company") and Seakinetics Corporation (Frankfurt: M90) announced that they have finalized the agreement affording Seakinetics Corporation a controlling interest in Marketing Concepts International. Seakinetics will participate in funding initiatives as required to provide additional working capital to Marketing Concepts. These funding infusions are expected to fuel substantial growth in revenues.

The Company's President and CEO, Kenneth W Mann confirmed that the final agreement provides for an exchange of treasury stock from each Company as follows: Seakinetics, which currently trades on the Frankfurt Exchange at roughly 1.75 Euro per share, will deposit into the Company's trust account 160,000 restricted shares of its stock with a current market value of USD $328,000 in exchange for a 37.5% interest in Marketing Concepts International. Seakinetics will retain a further option for an additional 15% of treasury stock issued under rule 144 at a discount of 10% to market.

Seakinetics will be appointing one board member to the Board of Directors of Marketing Concepts International within the next 60 days.

Seakinetics was established for the purpose of designing, developing, marketing and investing in innovative technologies and services in the renewable energy field. Seakinetics' mission is to be the best in finding solutions for renewable energy today and for the foreseeable future.

DNAPRINT GENOMICS (OTCBB: DNAG)

"Up 80.00% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/DNAG.php

DNAPrint Genomics, Inc. engages in the research and development of genomic products, and provides scientific services and tests to the genealogy, forensic, pharmaceutical, and genetics markets in the United States. Its primary product under development is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients. The company's other products under development include PT-501 for the treatment of attention deficit hyperactivity disorder; PT-502 for the treatment of drug addiction; and PT-503 for the treatment of depression. DNAPrint Genomics also develops diagnostic tests, including OVANOME for ovarian cancer, STATINOME for the safety of statins, DIABETES-CD59 for pre-diabetes diabetic complications; and PONV for post-operative nausea and vomiting. In addition, it offers DNAWitness product suite for the forensics market to determine genetic heritage from DNA samples obtained from crime scenes; and ANCESTRYbyDNA and EURO-DNA, which are genealogy products that provide an inference of an individual's genetic ancestry or heritage. Further, the company provides sequencing and genotyping services to industrial customers. DNAPrint Genomics has strategic alliances with Moffitt Cancer Center, and Beth Israel Deaconess Medical Center; and a collaborative research agreement with Beth Israel. It also has a license agreement with Harvard Medical School, and a research sponsorship agreement with Massachusetts College of Pharmacy and Health Sciences. The company, formerly known as Lexington Energy, Inc., was incorporated in 1983 and is based in Sarasota, Florida.

DNAG News:

February 1 - Nanobac Pharmaceuticals Inc. Signs LOI for the Acquisition of DNAPrint Genomics

Nanobac Pharmaceuticals Inc. (OTCBB: NNBP) ("Nanobac" or "the Company”) announced a jointly signed letter of intent for the acquisition of DNAPrint Genomics, Inc. (OTCBB: DNAG) (“DNAPrint” or DNAP). With the acquisition, which is subject to DNAPrint Genomics shareholder approval, Nanobac becomes one of a select group of next-generation drug and diagnostics developers, applying advanced computational methods and systematic genome-based approaches to streamline clinical product development. Nanobac adds advanced drug and diagnostics development programs, key patents and patent applications, and a proprietary product modeling platform to its existing initiatives, and expands its focus into multiple disease sites for both Diagnostics and Therapeutics.

The combined company would have annualized revenue of approximately $5,000,000, developing drug pipeline and product development collaborations with Harvard/Beth Israel Deaconess Medical Center, Mayo Clinic, Cleveland Clinic and Emory University.

DNAPrint Genomics has developed, patented and published various technologies for an improved, 21st century model of clinical product development - aimed at maximizing effectiveness, minimizing unintended effects, reducing costs and shifting the risk to reward ratio during clinical product development. These tools include extensively validated and published genome assays for individualized assessments of genetic ancestry on multiple levels (consumer products segment), tools for the inference of physical characteristics for the forensics market, tools for the inference of patient proclivities to respond to treatments (pharmacogenomics) and meta-analytical systems for computationally modeling the biology of clinical products for a more intelligent approach to drug and diagnostic development. DNAG's primary objective has been, and Nanobac's primary objective will be, to develop progressive theranostics drugs, which combine extensively modeled drugs with genomics-derived intelligence to create more economical and powerful drug/test combination products with superior performance parameters. DNAG's flagship product, PT-401, is expected to result in more effective treatment of anemia, and its Protectin(TM) (CD-59) diagnostic test is expected to allow patients and their physicians to more effectively manage the risks and treatment decisions for diabetes. DNAG supports its clinical programs, in part, through the sale of consumer genetics tests genotyping services on a contractual basis.

“Dr Hector Gomez has been on the Company’s advisory board giving Nanobac the benefit of evaluating DNAG’s technologies and portfolio of products,” said Dr. Benedict Maniscalco, Co-Chairman and Chief Medical Officer of Nanobac Pharmaceuticals. “Combining our diagnostic portfolios, specifically DNAP’s Protectin™ and Nanobac’s NB2 has the potential to play a significant role in the early diagnosis of vascular disease and could potentially help in identifying early signs and progression of cardiovascular disease,” Dr. Maniscalco concluded.

"The Protectin(TM) test will be used to identify diabetics at risk of developing vascular complications," said Dr. Gomez, Chairman of DNAP. "Protectin(TM) is anticipated to become a new tool in the complex understanding of Diabetes and could potentially replace HbA1c, the current test used to evaluate glucose control. Combined with Nanobac's diagnostic portfolio, Protectin(TM) is expected to dramatically increase the physician's ability to diagnose patients at significant cardiovascular risk," concluded Dr. Gomez.

According to Global Industry Analysts, the international global diabetes diagnostic supplies market is expected to grow to US$15.4 billion by 2010. This indicates significant potential for the Protectin™ test. Additionally, cardiovascular diagnostics will see a high rate of growth also, increasing from $11.9 billion in 2007 to $21.4 billion by the end of 2012. The cardiovascular diagnostics market represents one of the largest sectors within the diagnostics industry, chiefly due to the high prevalence rate of and high mortality rate from cardiovascular disease.

DNAG’s flagship PT-401 therapeutic, in pre-clinical stages, is a genetically engineered erythropoietin dimmer (double form), which elicits a heartier, longer lasting increase in hematocrit for anemic patients. The singlet form of erythropoietin was introduced by Amgen Corporation in 1989, and enjoys a $2B in annual sales. A successfully approved PT-401 alternative is expected to allow physicians to treat patients with less drug and at less frequent intervals, at significant savings, while at the same time, increasing the consistency of therapeutic response.

Nanobac Pharmaceuticals is the leader in research and treatment of degenerative diseases stemming from nanobacterial infections. This infection is implicated in the formation of disease-causing calcification and plaque in the circulatory system and vital organs. Nanobac Pharmaceuticals markets diagnostics and prescription nanobiotic medications demonstrated to safely and effectively treat an underlying cause of atherosclerosis, coronary heart disease and other degenerative diseases.

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit the company's website at www.nanobac.com.

CENTERLINE HOLDING COMPANY (OTC: CLNH)

"Up 73.68% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/CLNH.php

Centerline Capital Group, a subsidiary of Centerline Holding Company, provides real estate financial and asset management services, including institutional debt and equity fund management, mortgage banking and primary and special loan servicing. As of September 30, 2008, Centerline had more than $14 billion of assets under management. Centerline is headquartered in New York, New York and has nine offices throughout the United States.

CLNH News:

November 12 - Centerline Holding Company Reports Third Quarter 2009 Financial Results

Centerline Holding Company (OTC: CLNH) (“Centerline” or the “Company”), the parent company of Centerline Capital Group, a provider of real estate financial and asset management services, announced financial results for the third quarter and nine months ended September 30, 2009.

Third Quarter 2009 Highlights:

* For the three months ended September 30, 2009, the Company reported a net loss attributable to Centerline shareholders(1) of ($5.38) per share, as compared to a net loss of ($3.03) per share for the three months ended September 30, 2008; earnings per share (“EPS”)(1), excluding certain items (primarily non cash), was ($0.08) for the three months ended September 30, 2009, as compared to EPS, excluding certain items (primarily non cash) of ($0.17), for the three months ended September 30, 2008;

* Net loss was driven primarily by: (i) lower business volume and lower interest income in the third quarter 2009, as compared to the same period in 2008; (ii) asset impairments in the Commercial Mortgage-Backed Securities (“CMBS”) and High-Yield Debt Funds Centerline manages; (iii) asset impairments on the Series B Freddie Mac Certificates and stabilization escrow; (iv) write-off of goodwill and intangible assets; (v) the loss reserve associated with Affordable Housing transactions; and (vi) a reserve against the remaining carrying value of Centerline's loan to American Mortgage Acceptance Company ("AMAC");

* Centerline paid down the outstanding balance of its senior credit facility debt by $68.7 million to $228.2 million, from 2008 year-end levels of $296.9 million and repaid $8.7 million of the $13.8 million CMBS term loan balance outstanding as of December 31, 2008. Since September 30, 2009 through the date of this press release, Centerline has paid down an additional $5.0 million of its senior credit facility debt;

* Centerline had direct assets under management (“AUM”)(2) of $13.4 billion as of September 30, 2009;

* Centerline originated $104.5 million of multifamily loans on behalf of Fannie Mae and Freddie Mac in the third quarter of 2009, and raised nearly $3.8 million of capital for Affordable Housing tax-credit funds; In October 2009, Centerline originated $73.7 million of additional multifamily loans and closed an additional $22.2 million of multifamily loans awaiting settlement on behalf of Fannie Mae and Freddie Mac, and raised over $14.4 million of capital for Affordable Housing tax-credit funds;

* As of September 30, 2009, the Company’s Fannie Mae servicing portfolio had nine delinquent loans, with an outstanding balance of $47.3 million, representing 0.5% of its $8.8 billion agency servicing portfolio; in addition, as of September 30, 2009, there were three loans in Fannie Mae Real Estate Owned properties with a combined outstanding balance of $15.8 million that were formerly in the Centerline portfolio, subject to final resolution and loss sharing settlement;

* As of September 30, 2009, Centerline was the named special servicer on a portfolio of $109.7 billion. At that date, $3.8 billion (or 3.46% of the portfolio) was delinquent, compared to an industry average of 4.23%, as reported by Trepp;

* Centerline launched a new business initiative through its Agency Lending Products Group: the multifamily small loan program; and

* The Company continues discussions with Island Capital Group LLC, and others, to accomplish a recapitalization of Centerline.

(1) See “Selected Financial Data” for a reconciliation of GAAP net income (loss) attributable to Centerline Holding Company shareholders to EPS (excluding certain items, primarily non-cash).

(2) See AUM table and footnotes.

SUNESIS PHARMACEUTICALS INCORPORATED (NASDAQ: SNSS)

"Up 24.07% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/SNSS.php 

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer.

SNSS News:

December 28 - Sunesis Pharmaceuticals Regains NASDAQ Compliance

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced that it has received notification from The NASDAQ Stock Market that it has regained compliance with the minimum $1.00 per share bid price requirement. As required under NASDAQ's Listing Rules, to regain compliance, the Company was required to evidence a closing bid price of $1.00 per share or more for at least ten consecutive days. On December 23, 2009, the closing bid price of the Company's common stock was $1.34 per share, the tenth consecutive day the stock price had closed above $1.00 per share.

OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.

Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov/ and FINRA at http://www.finra.org/.

Disclosure: OTCPicks.com has been compensated two hundred and fifty thousand free trading shares by a third party (TEN Associates, LLC) for ALKN advertising and promotional services.